RxDoctor Payments Data

Lilliam Garcia, MD

Internal Medicine · Fort Lauderdale, FLNPI 1023218328

Payments from drug & device makers

$1,495in general payments, 2019–2025

Across 68 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$192
  • GSK$189
  • Esperion Therapeutics, Inc.$156
  • Pfizer$151
  • Novartis$142
  • Novo Nordisk$109
  • plus $556 from 13 others

What the payments were for

  • Food & beverage$1,495100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,495 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$52,029
Medicare patients
115
Services billed
575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide133$151,480
EliquisApixaban64$81,536
MounjaroTirzepatide56$60,227
XareltoRivaroxaban43$55,955
Repatha SureclickEvolocumab55$39,486
TrulicityDulaglutide13$26,681
Breo ElliptaFluticasone/Vilanterol30$24,426
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$19,982
Tresiba Flextouch U-200Insulin Degludec19$17,266
Tresiba Flextouch U-100Insulin Degludec16$11,160
LinzessLinaclotide11$6,945
Rosuvastatin Calcium594$6,710
Rivastigmine21$4,099
Levothyroxine Sodium332$3,873
Omeprazole238$3,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$109$151,480133 claims
Lilly USA, LLCMounjaro, Trulicity$106$86,90869 claims
PfizerEliquis, Paxlovid$151$82,96591 claims
Johnson & JohnsonXarelto$58$55,95543 claims
GSKBreo Ellipta, Trelegy Ellipta$189$44,40845 claims
AbbVieLinzess, Synthroid$29$10,20639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →